Therapeutic human papillomavirus vaccines in head and neck cancer: A systematic review of current clinical trials
| Autor: | Christian Grønhøj, Christian von Buchwald, Katrine Schneider, Christoffer Holst Hahn |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Disease 03 medical and health sciences 0302 clinical medicine Immune system Internal medicine medicine Humans Papillomavirus Vaccines Human papillomavirus Adverse effect Clinical Trials as Topic General Veterinary General Immunology and Microbiology business.industry Immunogenicity Head and neck cancer Public Health Environmental and Occupational Health medicine.disease Vaccine therapy Clinical trial Oropharyngeal Neoplasms 030104 developmental biology Infectious Diseases Head and Neck Neoplasms 030220 oncology & carcinogenesis Molecular Medicine business |
| Zdroj: | Vaccine. 36(45) |
| ISSN: | 1873-2518 |
| Popis: | Objectives This systematic review provides an overview of the current clinical trials investigating therapeutic vaccines for HPV+ head and neck cancer and discusses the future directions of therapeutic vaccine therapy. Materials and methods A systematic search was conducted in PubMed, EMBASE, Cochrane and clinicaltrials.gov for clinical trials involving therapeutic vaccines. We included studies initiated between 2000 and 2018 with patients diagnosed with HPV+ head and neck cancer and extracted data concerning type of vaccine therapy, adverse events, immunogenicity and clinical outcome measures (e.g. tumour response, progression-free survival and overall survival). Results We identified 11 studies (n = 376 patients) initiated between year 2005 and 2017. Four studies (n = 34) presented preliminary results in patients with incurable, recurrent loco-regional or distant metastatic disease indicating a positive immune response with 74% (n = 25/34 patients) having elevated antibody levels, IFN-γ and/or T-cell response. Five studies presented data on the vaccines’ safety profile, demonstrating predominantly grade 1 and 2 toxicity. Three studies evaluated the clinical outcome – one study showed no complete or partial response, one study demonstrated stable disease as the best tumour response in 64% (n = 9/14 patients) and one study showed a 33% overall response rate: one patient with a complete response and seven patients with a partial response. Conclusions Treatment with therapeutic vaccines is a promising and seemingly safe strategy for patients with HPV+ head and neck cancer. However, there are not enough data to draw any further conclusions and clinical outcome measures and tumour responses to the vaccines are still missing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect